Access the full text.
Sign up today, get DeepDyve free for 14 days.
M. Brackbill, R. Kidd, April Abdoo, James Warner, A. Harralson (2009)Frequency of CYP3A4, CYP3A5, CYP2C9, and CYP2C19 variant alleles in patients receiving clopidogrel that experience repeat acute coronary syndrome
Heart and Vessels, 24
T. Geisler, E. Schaeffeler, J. Dippon, S. Winter, Verena Buse, C. Bischofs, C. Zuern, K. Moerike, M. Gawaz, M. Schwab (2008)CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation.
Pharmacogenomics, 9 9
J. Goldstein (2001)Clinical relevance of genetic polymorphisms in the human CYP2C subfamily.
British journal of clinical pharmacology, 52 4
D. Trenk, W. Hochholzer, M. Fromm, Ligia Chialda, A. Pahl, C. Valina, C. Stratz, Peter Schmiebusch, H. Bestehorn, H. Büttner, F. Neumann (2008)Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents.
Journal of the American College of Cardiology, 51 20
S. Scott, K. Sangkuhl, C. Stein, J. Hulot, J. Mega, D. Roden, T. Klein, M. Sabatine, Julie Johnson, A. Shuldiner (2013)Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update
Clinical Pharmacology & Therapeutics, 94
Fumie Takakubo, Akira Kuwano, Ikuko Kondo (1996)Evidence that poor metabolizers of (S)-mephenytoin could be identified by haplotypes of CYP2C19 in Japanese.
Pharmacogenetics, 6 3
L. Bathum, T. Hansen, M. Hørder, K. Brøsen (1998)A dual label oligonucleotide ligation assay for detection of the CYP2C19*1, CYP2C19*2, and CYP2C19*3 alleles involving time-resolved fluorometry.
Therapeutic drug monitoring, 20 1
E. Elhaik, T. Tatarinova, D. Chebotarev, I. Piras, Carla Calò, Antonella Montis, Manuela Atzori, M. Marini, S. Tofanelli, P. Francalacci, Luca Pagani, C. Tyler-Smith, Yali Xue, F. Cucca, T. Schurr, Jill Gaieski, Carlalynne Melendez, M. Vilar, A. Owings, R. Gómez, R. Fujita, F. Santos, D. Comas, O. Balanovsky, E. Balanovska, P. Zalloua, H. Soodyall, R. Pitchappan, Arunkumar Ganeshprasad, M. Hammer, L. Matisoo-Smith, R. Wells, Oscar Cooper, Oscar Acosta, Syama Adhikarla, C. Adler, J. Bertranpetit, Andrew Clarke, A. Cooper, Clio Sarkissian, W. Haak, Marc Haber, Li Jin, M. Kaplan, Hui Li, Shilin Li, B. Martínez-Cruz, Nirav Merchant, John Mitchell, L. Parida, D. Platt, L. Quintana-Murci, C. Renfrew, D. Lacerda, A. Royyuru, José Sandoval, A. Santhakumari, David Hernanz, Pandikumar Swamikrishnan, J. Ziegle (2014)Geographic population structure analysis of worldwide human populations infers their biogeographical origins
Nature Communications, 5
Daniel Strand, Daejin Kim, D. Peura (2016)25 Years of Proton Pump Inhibitors: A Comprehensive Review
Gut and Liver, 11
E. Elhaik, T. Tatarinova, D. Chebotarev, I. Piras, C. Caló, Antonella Montis, Manuela Atzori, M. Marini, S. Tofanelli, P. Francalacci, Luca Pagani, C. Tyler-Smith, Yali Xue, F. Cucca, T. Schurr, Jill Gaieski, Carlalynne Melendez, M. Vilar, A. Owings, R. Gómez, R. Fujita, F. Santos, D. Comas, O. Balanovsky, E. Balanovska, P. Zalloua, H. Soodyall, R. Pitchappan, Arunkumar Ganeshprasad, M. Hammer, L. Matisoo-Smith, R. Wells (2016)Corrigendum: Geographic population structure analysis of worldwide human populations infers their biogeographical origins
Nature Communications, 7
Mol Biol Evol, 33
(2013)CYP2C19*2, CYP2C19*3, CYP2C19*17 Allele and genotype frequencies in clopidogrel-treated patients with coronary heart disease from the Russian population
(2011)A comparative study of CYP2C19 gene polymorphism in children living in the Astrakhanian region
F. Vasilyev, D. Danilova, V. Kaimonov, Y. Chertovskih, N. Maksimova (2016)Frequency distribution of polymorphisms of CYP2C19, CYP2C9, VKORC1 and SLCO1B1 genes in the Yakut population
Research in Pharmaceutical Sciences, 11
L. Hillman, R. Yadlapati, A. Thuluvath, M. Berendsen, J. Pandolfino (2017)A review of medical therapy for proton pump inhibitor nonresponsive gastroesophageal reflux disease.
Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 30 9
J. Mega, T. Simon, J. Collet, Jeffrey Anderson, E. Antman, K. Bliden, C. Cannon, N. Danchin, B. Giusti, P. Gurbel, B. Horne, J. Hulot, A. Kastrati, G. Montalescot, F. Neumann, Lei-Bin Shen, D. Sibbing, P. Steg, D. Trenk, S. Wiviott, M. Sabatine (2010)Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
JAMA, 304 16
Xue-Qing Li, T. Andersson, Marie Ahlström, L. Weidolf (2004)Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.
Drug metabolism and disposition: the biological fate of chemicals, 32 8
A. Aynacioglu, C. Sachse, A. Bozkurt, S. Kortunay, M. Nacak, Thomas Schröder, S. Kayaalp, I. Roots, J. Brockmöller (1999)Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population
Clinical Pharmacology & Therapeutics, 66
K. Mirzaev, D. Sychev, G. Arutyunyan, A. Yugay, D. Andreev (2013)Cytochrome 2C19 Enzyme Polymorphism Frequency in Different Indigenous Ethnic Groups in Russian Federation: A Systematic Review
Journal of Pharmacogenomics and Pharmacoproteomics, 5
A. Polonikov, A. Kharchenko, M. Bykanova, S. Sirotina, I. Ponomarenko, A. Bocharova, Kseniya Vagaytseva, V. Stepanov, O. Bushueva, M. Churnosov, M. Solodilova (2017)Polymorphisms of CYP2C8, CYP2C9 and CYP2C19 and risk of coronary heart disease in Russian population.
O. Makeeva, V. Stepanov, V. Puzyrev, D. Goldstein, I. Grossman (2008)Global pharmacogenetics: genetic substructure of Eurasian populations and its effect on variants of drug-metabolizing enzymes.
Pharmacogenomics, 9 7
(2014)Prevalence of CYP2C19*2 (cG681A,rs4244285) polymorphic markers in Dagestan mountaineers population, its role for pharmacotherapy individualization
(2012)The study of cytochrome P-450 CYP2C19 gene polymorphisms in population of Tatars living in Republic of Tatarstan
D. Sibbing, W. Koch, Daniela Gebhard, S. Braun, Julia Stegherr, T. Morath, A. Schömig, N. Beckerath, A. Kastrati, Tibor Schuster (2010)Response to Letter Regarding Article, “Cytochrome 2C19*17 Allelic Variant, Platelet Aggregation, Bleeding Events, and Stent Thrombosis in Clopidogrel-Treated Patients With Coronary Stent Placement”
U. Klotz (2006)Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem.
International journal of clinical pharmacology and therapeutics, 44 7
Deepak Bhatt, B. Cryer, C. Contant, Marc Cohen, Á. Lanas, T. Schnitzer, T. Shook, P. Lapuerta, M. Goldsmith, L. Laine, B. Scirica, S. Murphy, C. Cannon (2010)Clopidogrel with or without omeprazole in coronary artery disease.
The New England journal of medicine, 363 20
Javeed Tantray, K. Reddy, K. Jamil, Y. Kumar (2017)Pharmacodynamic and cytogenetic evaluation in CYP2C19*2 and CYP2C19*3 allelomorphism in South Indian population with clopidogrel therapy.
International journal of cardiology, 229
R. Gray, H. Coleman, K. Lau, C. Mccaughey, P. Coyle, L. Murray, B. Johnston (2015)Heller's myotomy and pneumatic dilatation in the treatment of achalasia: a population-based case-control study assessing long-term quality of life.
Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 30 3
R. Cardoso, A. Benjo, J. DiNicolantonio, Daniel Garcia, F. Macedo, Georges El-Hayek, G. Nadkarni, S. Gili, M. Iannaccone, Ioannis Konstantinidis, J. Reilly (2015)Incidence of cardiovascular events and gastrointestinal bleeding in patients receiving clopidogrel with and without proton pump inhibitors: an updated meta-analysis
Open Heart, 2
J. Collet, J. Hulot, A. Pena, E. Villard, J. Esteve, J. Silvain, L. Payot, D. Brugier, G. Cayla, F. Beygui, G. Bensimon, C. Funck-Brentano, G. Montalescot (2009)Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study
The Lancet, 373
(2010)Frequencies the “slow” allele variants of the genes coding isoenzymes of cytochrome Р450 CYP2D6, CYP2C19, CYP2C9 in Karachaevs and Circassians
E. Gaikovitch, I. Cascorbi, P. Mrozikiewicz, J. Brockmöller, R. Frötschl, K. Köpke, T. Gerloff, Jury Chernov, I. Roots (2003)Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population
European Journal of Clinical Pharmacology, 59
J. Swen, M. Nijenhuis, A. Boer, L. Grandia, A. Zee, H. Mulder, G. Rongen, R. Schaik, T. Schalekamp, D. Touw, J. Weide, B. Wilffert, V. Deneer, H. Guchelaar (2011)Pharmacogenetics: From Bench to Byte— An Update of Guidelines
Clinical Pharmacology & Therapeutics, 89
S. Sim, C. Risinger, M. Dahl, E. Aklillu, M. Christensen, L. Bertilsson, M. Ingelman-Sundberg (2006)A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants
Clinical Pharmacology & Therapeutics, 79
J. Mega, S. Close, S. Wiviott, Lei-Bin Shen, R. Hockett, J. Brandt, J. Walker, E. Antman, W. Macias, E. Braunwald, M. Sabatine (2009)Cytochrome p-450 polymorphisms and response to clopidogrel.
The New England journal of medicine, 360 4
Irina Pugach, Rostislav Matveev, V. Spitsyn, Sergey Makarov, I. Novgorodov, V. Osakovsky, M. Stoneking, B. Pakendorf (2015)The Complex Admixture History and Recent Southern Origins of Siberian Populations
Molecular Biology and Evolution, 33
B. Giusti, A. Gori, R. Marcucci, C. Saracini, I. Sestini, R. Paniccia, P. Buonamici, D. Antoniucci, R. Abbate, G. Gensini (2009)Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis.
The American journal of cardiology, 103 6
D. Sychev, N. Denisenko, Z. sizova, A. Grachev, K. Velikolug (2015)The frequency of CYP2C19 genetic polymorphisms in Russian patients with peptic ulcers treated with proton pump inhibitors
Pharmacogenomics and Personalized Medicine, 8
H. Roh, M. Dahl, G. Tybring, H. Yamada, Y. Cha, L. Bertilsson (1996)CYP2C19 genotype and phenotype determined by omeprazole in a Korean population.
Pharmacogenetics, 6 6
Xia-qin Wang, Chen Shen, Bang-Ning Wang, Xiao-hui Huang, Zhangyue Hu, Jun Li (2015)Genetic polymorphisms of CYP2C19 2 and ABCB1 C3435T affect the pharmacokinetic and pharmacodynamic responses to clopidogrel in 401 patients with acute coronary syndrome.
Gene, 558 2
L. Bonello, S. Arméro, O. Mokhtar, J. Mancini, P. Aldebert, N. Saut, N. Bonello, P. Barragan, S. Arques, Marie-Paule Giacomoni, Caroline Bonello-Burignat, M-N Bartholomei, F. Dignat-George, L. Camoin-Jau, F. Paganelli (2010)Clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2C19*2 loss of function polymorphism.
Journal of the American College of Cardiology, 56 20
M. Scordo, A. Caputi, Concetta D'Arrigo, G. Fava, E. Spina (2004)Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population.
Pharmacological research, 50 2
É. Crubézy, S. Amory, C. Keyser, C. Bouakaze, Martin Bodner, M. Gibert, Alexander Röck, W. Parson, A. Alexeev, Bertrand Ludes (2010)Human evolution in Siberia: from frozen bodies to ancient DNA
BMC Evolutionary Biology, 10
N. Denisenko, D. Sychev, Z. Sizova, V. Smirnov, K. Ryzhikova, Z. Sozaeva, E. Grishina (2017)Urine metabolic ratio of omeprazole in relation to CYP2C19 polymorphisms in Russian peptic ulcer patients
Pharmacogenomics and Personalized Medicine, 10
Neha Deshpande, S. V., Ravi V., Murthy V., S. M, R. Banerjee, M. Tandan, N. D. (2016)Rapid and ultra-rapid metabolizers with CYP2C19*17 polymorphism do not respond to standard therapy with proton pump inhibitors
Meta Gene, 9
K. Mirzaev, E. Zelenskaya, O. Barbarash, V. Ganyukov, K. Apartsin, N. Saraeva, K. Nikolaev, K. Ryzhikova, G. Lifshits, D. Sychev (2017)CYP2C19 polymorphism frequency in Russian patients in Central Russia and Siberia with acute coronary syndrome
Pharmacogenomics and Personalized Medicine, 10
R. Teixeira, P. Monteiro, G. Marques, J. Pêgo, M. Lourenço, C. Tavares, A. Reboredo, S. Monteiro, F. Gonçalves, M. Ferreira, M. Freitas, G. Ribeiro, L. Providência (2012)CYP2C19*2 and prognosis after an acute coronary syndrome: Insights from a Portuguese center.
Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology, 31 4
C. Kuo, Chien-Yu Lu, H. Shih, Chung-Jung Liu, Meng-Chieh Wu, Huang-Ming Hu, W. Hsu, Fang-Jung Yu, Deng-Chyang Wu, F. Kuo (2014)CYP2C19 polymorphism influences Helicobacter pylori eradication.
World journal of gastroenterology, 20 43
K. Hagymási, K. Müllner, L. Herszényi, Z. Tulassay (2011)Update on the pharmacogenomics of proton pump inhibitors.
Pharmacogenomics, 12 6
J Vasc Surg, 49
AbstractBackground:The focus of the study is to determine the prevalence of CYP2C19 alleles, associated with the risk of changes in the pharmacological response to clopidogrel and proton pump inhibitors in patients with acute coronary syndrome (ACS) and gastric ulcer from Russian and Yakut ethnic groups.Methods:The research included 411 patients with ACS (143 Russians and 268 Yakuts) and 204 patients with histologically confirmed gastric ulcer (63 Russians and 141 Yakuts). Genotyping of 681G>A and 636G>A polymorphisms was performed by using polymerase real-time chain reaction.Results:In both ethnic groups, Hardy-Weinberg equilibrium was followed in a distribution of alleles and genotypes in the population (p>0.05). The 681A allele frequency in the Yakut ethnic group was higher than in the Russian group: 17.53% vs. 8.39% (p=0.001). No statistically significant difference was found in the frequency of 636A in Yakuts and Russians with ACS: 3.92% vs. 3.50% (p=0.840). While comparing the frequency distribution of alleles 681A (13.49% vs. 14.54%, p=0.878) and 636A (7.94% vs. 7.80%, p=1) in patients with a gastric ulcer from Russian and Yakut ethnic groups, no significant difference was found in carrier frequency.Conclusions:The results of the present study may be helpful for developing guidelines for CYPC19 genotype-directed antiplatelet therapy for Yakut and Russian patients.
Drug Metabolism and Drug Interactions – de Gruyter
Published: Jun 27, 2018
Access the full text.
Sign up today, get DeepDyve free for 14 days.